Q1 2020 Photocure ASA Earnings Call Transcript
Well, good afternoon to everyone in Norway. It is 9 a.m. in the U.S., so good morning on my end. Welcome to Photocure's results for first quarter 2020. I'm Dan Schneider, President and CEO. Joining me today will also be Erik Dahl, CFO.
Next slide. The usual disclaimers are in place for today's presentation.
Slide 3. So I'm going to take you a little bit through who we are. We've got a lot of new investors who've joined the Photocure family. So I'll tell you a little bit about the company and a little bit about the product, and then we'll get into some of the results. Photocure at a glance; we have our corporate offices in Oslo, Norway with a U.S. office in Princeton, New Jersey. We are a commercial stage pharmaceutical company focused solely on bladder cancer with operations -- direct operations in the U.S. and the Nordics and partnerships around the world.
Our revenue growth is in excess of 23%, and we have over NOK 330 million in global in-market sales. Our market cap today is approximately NOK 1.7 billion and average
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
